Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.26
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.26
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.91 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$771.80M
Enterprise ValueAU$1.53K
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)56.1
Beta0.62
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.04
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.58
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.13Price Target Upside38.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.15
Revenue Forecast (FY)AU$849.38M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth indicates expanding patient volumes and stronger utilisation of the clinic and hospital network. This durable top-line expansion supports scale economics, funds reinvestment in imaging equipment and sites, and underpins growth momentum over months.
High Gross MarginA very high gross margin reflects low direct costs per exam and efficient service delivery. Sustained margin levels provide a structural cushion against input cost pressure, enable continuing investment in technology and reporting capabilities, and support long-term operating leverage.
Improved LeverageImproved debt-to-equity reduces refinancing and solvency risk, enhancing financial flexibility. Lower leverage supports planned capital expenditure on scanners and clinics, and provides capacity to pursue contracts or selective acquisitions without creating acute balance sheet strain.
Bears Say
Low Net MarginA sub-1% net margin shows the business struggles to convert strong top-line growth into durable profits after overhead and non-operating costs. This limits retained earnings for reinvestment, constrains shareholder returns, and increases vulnerability to rising costs or reimbursement pressure over time.
Falling Free Cash FlowA nearly 59% drop in free cash flow materially weakens internal funding for maintenance, replacement of capital-intensive imaging equipment, and organic expansion. Persistently low FCF may force reliance on external financing and reduce strategic optionality over the medium term.
Weak Return On EquityROE near zero indicates invested capital is generating minimal shareholder returns despite revenue growth. Over months this suggests capital deployment is not yet efficient, which can hamper the company's ability to attract new capital or justify further equity-funded expansion.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$1.91 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$771.80M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 40 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.033 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.13 (38.27% Upside)
AU$3.13 (38.27% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth AU$125.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.13
▲(38.27% Upside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Imagion Biosystems Ltd.
―








